● EDITORIAL
2026/10 Results check-in — Eli Lilly (10-Q)
Eli Lilly's third-quarter 2026 Form 10-Q, filed October 29, shows revenue of $24.40 billion, up 39% from $17.60 billion a year earlier. The top line is still compounding at a rapid clip. The profit lines have not kept pace. Net income rose 16% year over year to $6.45 billion, and diluted EPS has…